Decreased antibiotic exposure using a procalcitonin protocol for respiratory infections and sepsis in US community hospitals (ProCommunity)

References

• Center for Disease Control and Prevention. Antibiotic resistance threats in the United States. U.S. Washington, D.C.: Department of Human and Health Services; 2020.
   Google Scholar
• Jensen JU, Hein L, Lundgren B, et al. Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open. 2012;2(2):e000635.
   PubMed Web of Science ®Google Scholar
• Stevens V, Dumyati G, Fine LS, et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53(1):42–48.
   PubMed Web of Science ®Google Scholar
• Antharam VC, Li EC, Ishmael A, et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol. 2013;51(9):2884–2892.
   PubMed Web of Science ®Google Scholar
• Brown KA, Khanafer N, Daneman N, et al. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013;57(5):2326–2332.
   PubMed Web of Science ®Google Scholar
• Fridkin S, Baggs J, Fagan R, et al. Vital signs: improving antibiotic use among hospitalized patients. MMWR Morb Mortal Wkly Rep. 2014;63(9):194–200.
   PubMed Web of Science ®Google Scholar
• Interagency Task Force for Combating Antibiotic-Resistant Bacteria. National action plan for combating antibiotic resistant bacteria. In: The white house, editor. Washington, DC: Interagency Task Force for Combating Antibiotic-Resistant Bacteria; 2015. p. 62.
   Google Scholar
• Hohn A, Heising B, Schütte J-K, et al. Procalcitonin-guided antibiotic treatment in critically ill patients. Langenbecks Arch Surg. 2017;402(1):1–13.
   PubMed Web of Science ®Google Scholar
• Hey J, Thompson-Leduc P, Kirson NY, et al. Procalcitonin guidance in patients with lower respiratory tract infections: a systematic review and meta-analysis. Clin Chem Lab Med. 2018;56(8):1200–1209.
   PubMed Web of Science ®Google Scholar
• Claxton A, Iankova I, Thompson-Leduc P, et al. Efficacy and safety of procalcitonin guidance in patients with suspected or confirmed sepsis: a systematic review and meta-analysis*. Crit Care Med. 2018;46(9):1560–1698.
   PubMed Web of Science ®Google Scholar
• Bouadma L, Luyt C-E, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. The Lancet. 2010;375(9713):463–474.
   PubMed Web of Science ®Google Scholar
• Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014;34(4):263–273.
   PubMed Web of Science ®Google Scholar
• Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, et al. Procalcitonin to reduce long-term infection-associated adverse events in sepsis. a randomized trial. Am J Respir Crit Care Med. 2021;203(2):202–210.
   PubMed Web of Science ®Google Scholar
• Mendez CM, Harrington DW, Christenson P, et al. Impact of hospital variables on case mix index as a marker of disease severity. Popul Health Manag. 2014;17(1):28–34.
   PubMed Web of Science ®Google Scholar
• Albrich WC, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”: an international, multicenter poststudy survey (ProREAL). Arch Intern Med. 2012;172(9):715–722.
   PubMed Web of Science ®Google Scholar
• Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379(3):236–249.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. Jama. 2009;302(10):1059–1066.
   PubMed Web of Science ®Google Scholar
• Balk RA, Kadri SS, Cao Z, et al. Effect of procalcitonin testing on health-care utilization and costs in critically ill patients in the United States. Chest. 2017;151(1):23–33.
   PubMed Web of Science ®Google Scholar
• Chu DC, Mehta AB, Walkey AJ. Practice patterns and outcomes associated with procalcitonin use in critically ill patients with sepsis. Clin Infect Dis. 2017;64(11):1509–1515.
   PubMed Web of Science ®Google Scholar
• Broyles MR. Impact of procalcitonin-guided antibiotic management on antibiotic exposure and outcomes: real-world evidence. open forum infect dis. Fall. 2017;4(4):ofx213.
   Google Scholar
• Walsh TL, DiSilvio BE, Hammer C, et al. Impact of procalcitonin guidance with an educational program on management of adults hospitalized with pneumonia. Am J Med. 2018;131(2):201 e1–201 e8.
   Web of Science ®Google Scholar
• Nolin TD. Vancomycin and the risk of AKI: now clearer than Mississippi Mud. Clin J Am Soc Nephrol. 2016;11(12):2101–2103.
   PubMed Web of Science ®Google Scholar